March 10 (Reuters) - Neogenomics Inc ( NEO ):
* NEOGENOMICS EXPANDS ONCOLOGY TESTING REACH IN THE
NORTHEAST WITH
ACQUISITION OF PATHLINE
* NEOGENOMICS INC ( NEO ): SYNERGIES FROM TRANSACTION EXPECTED TO
YIELD
ANNUAL COST REDUCTIONS, WHICH WILL BE ACCRETIVE TO AEBITDA
STARTING IN 2026
Source text:
Further company coverage: